Evidence map›Paper›PMID 30408422›Full record

ReviewExpert opinion on biological therapy2018

Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies.

Michael Whitehead, Sanjeewa Wickremasinghe, Andrew Osborne, Peter Van Wijngaarden, Keith R Martin

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on biological therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 4 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 4 syntheses or guidelines pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cardiometabolic factors and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michael Whiteheada John van Geest Centre for Brain Repair, Department of Clinical Neurosciences , University of Cambridge , Cambridge , UK.
Sanjeewa Wickremasingheb Centre for Eye Research Australia , University of Melbourne and Royal Victorian Eye and Ear Hospital , Melbourne , Australia.
Andrew Osbornea John van Geest Centre for Brain Repair, Department of Clinical Neurosciences , University of Cambridge , Cambridge , UK.
Peter Van Wijngaardenb Centre for Eye Research Australia , University of Melbourne and Royal Victorian Eye and Ear Hospital , Melbourne , Australia.
Keith R Martina John van Geest Centre for Brain Repair, Department of Clinical Neurosciences , University of Cambridge , Cambridge , UK.
University of Cambridge · GBUniversity of Melbourne · AUAddenbrooke's Hospital · GB

Funding

Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

introductionDiabetic retinopathy (DR) is the leading cause of vision loss in the working age population of the developed world. DR encompasses a complex pathology, and one that is reflected in the variety of currently available treatments, which include laser photocoagulation, glucocorticoids, vitrectomy and agents which neutralize vascular endothelial growth factor (VEGF). Whilst these options demonstrate modest clinical benefits, none is yet to fully attenuate clinical progression or reverse damage to the retina. This has led to an interest in developing novel therapies for the condition, such as mediators of angiopoietin signaling axes, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), oxidative stress inhibitors and vitriol viscosity inhibitors. Further, preclinical research suggests that gene therapy treatment for DR could provide significant benefits over existing treatments options. AREAS COVERED: Here we review the pathophysiology of DR and provide an overview of currently available treatments. We then outline recent advances made towards improved patient outcomes and highlight the potential of the gene therapy paradigm to revolutionize DR management. EXPERT OPINION: Whilst significant progress has been made towards our understanding of DR, further research is required to enable the development of a detailed spatiotemporal model of the disease. In addition, we hope that improvements in our knowledge of the condition facilitate therapeutic innovations that continue to address unmet medical need and improve patient outcomes, with a focus on the development of targeted medicines.

Indexed as

Therapies, InvestigationalAngiogenesis InhibitorsAnimalsDiabetic RetinopathyGenetic TherapyGlucocorticoidsHumansAngiogenesis InhibitorsGlucocorticoidsdiabetic macular edemaDiabetic retinopathyneovascularizationneuronal apoptosisvascular endothelial growth factor

Identifiers

PMID30408422
PMCPMC6299358
OpenAlexW2900068552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.